RxDoctor Payments Data

Adil Zahiruddin, MD

Allergy & Immunology · Cypress, TXNPI 1982048328

Payments from drug & device makers

$10,975in general payments, 2019–2025

Across 498 payments — averaging $22.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • Sanofi$2K
  • AstraZeneca$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$915
  • Optinose US, Inc.$680
  • Genentech USA, Inc.$483
  • plus $3K from 24 others

What the payments were for

  • Speaking & faculty fees$8958%
  • Food & beverage$10,05092%
  • Education$300%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,975 in reported general payments places this provider in the 65th percentile of 336 allergy & immunology providers in Texas.

See all allergy & immunology providers in Texas

Medicare billing

Part B allowed, 2024
$268,815
Medicare patients
121
Services billed
9,281

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab16$77,737
Dupixent SyringeDupilumab11$40,262
Breo ElliptaFluticasone/Vilanterol15$11,320
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$9,422
Advair HfaFluticasone Propion/Salmeterol11$7,730
Epinephrine22$4,579
Qvar RedihalerBeclomethasone Dipropionate12$4,129
Fluticasone Propionate39$1,701
Ipratropium Bromide59$1,455
Azelastine Hcl48$1,364
Albuterol Sulfate HfaAlbuterol Sulfate61$1,301
Montelukast Sodium66$649
Famotidine17$328
Methylprednisolone37$199
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav21$193

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta, Trelegy Ellipta$1,982$20,74228 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$18$4,12912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 336 allergy & immunology providers in Texas.

Other allergy & immunology in Cypress

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →